TL;DR
This study investigates the effectiveness of In Vitro Fertilization (IVF) for women with hypogonadotropic hypogonadism (HH), a condition characterized by low levels of reproductive hormones. The findings suggest that IVF is a viable and successful treatment option for these patients, yielding comparable reproductive outcomes to women with other infertility causes.
What Problem Does This Paper Address?
Hypogonadotropic hypogonadism (HH) is a rare cause of female infertility resulting from insufficient production of gonadotropin-releasing hormone (GnRH) by the hypothalamus or gonadotropins (FSH and LH) by the pituitary gland. This hormonal imbalance leads to underdeveloped ovaries and anovulation, making natural conception difficult. While assisted reproductive technologies like IVF have advanced significantly, there's been limited research specifically evaluating the reproductive outcomes of women with HH undergoing IVF. This is partly due to the rarity of HH and the potential for unique challenges, such as impaired uterine development due to long-term estrogen deficiency, which could affect pregnancy success and increase risks like preterm birth. This paper aims to fill this knowledge gap by analyzing the IVF outcomes of HH patients and comparing them to a control group.
Methods
The researchers conducted a retrospective analysis of 81 women with HH and 112 control patients who underwent oocyte retrieval at Peking University Third Hospital between 2010 and 2019.
- Patient Classification: HH patients were categorized into congenital HH (CHH) and acquired HH (AHH), with AHH further including functional hypothalamic amenorrhea (FHA) and pituitary HH (PHH). Control patients had infertility due to tubal or male factors.
- Controlled Ovarian Stimulation (COS):
- HH Patients: Received hormone replacement therapy (HRT) to promote uterine development, followed by ovarian stimulation using urinary human menopausal gonadotropin (HMG) alone or in combination with recombinant human FSH (rFSH).
- Control Patients: Underwent COS using GnRH agonist (GnRH-a) or antagonist (GnRH-ant) protocols.
- IVF Procedures: Standard IVF or intracytoplasmic sperm injection (ICSI) was performed based on semen analysis. Embryo transfer occurred on day 3 or 5 post-retrieval.
- Outcome Measures: Key metrics included hormone levels on the day of hCG administration, duration of stimulation, total gonadotropin dose, number of oocytes retrieved, fertilized embryos, two-pronuclear (2PN) embryos, transferable embryos, fertilization rate, 2PN rate, live birth rate (LBR), and cumulative live birth rate (CLBR). Preterm birth (PTB) rates were also analyzed.
- Statistical Analysis: Appropriate statistical tests (independent sample T test, Wilcoxon test, Chi-square test) were used to compare groups, with a p-value less than 0.05 considered statistically significant.
Datasets
The study utilized retrospective clinical data from 81 women diagnosed with hypogonadotropic hypogonadism (HH) and 112 control patients undergoing IVF at Peking University Third Hospital from 2010 to 2019. No new datasets were created or introduced.
Key Insights and Ideas
- HH Patients Respond Well to IVF: Despite lower baseline hormone levels, HH patients demonstrated comparable IVF outcomes (fertilization, embryo development) to controls, suggesting that standard IVF protocols can be effective.
- Stimulation Needs Differ: HH patients required longer stimulation periods and higher gonadotropin doses, likely to overcome their inherent hormonal deficiencies and stimulate the ovaries.
- Cumulative Success is High: The cumulative live birth rates (CLBRs) for HH patients, even after multiple cycles, were encouraging and comparable to general IVF populations, highlighting the long-term potential of IVF.
- Etiology Doesn't Significantly Impact IVF Outcomes: The study found no significant differences in IVF outcomes between congenital (CHH) and acquired (AHH) forms of HH, simplifying treatment considerations.
- HMG is a Cost-Effective Option: For HH patients, HMG alone proved to be a cost-effective and efficient choice for ovulation induction, comparable to more expensive combination therapies.
- Preterm Birth Risk Not Increased: Contrary to concerns about impaired uterine development, the study found that preterm birth rates in HH patients were not significantly higher than reported rates for other infertility causes, though caution is advised for twin pregnancies.
Key Results
- Hormonal Differences: HH patients had significantly lower basal levels of FSH, LH, estradiol (E2), androstenedione (A), and prolactin (PRL) compared to controls.
- Stimulation Requirements: HH patients required significantly longer stimulation (14 days vs. 11 days) and higher total gonadotropin doses (3487.5 IU vs. 2550 IU) than controls.
- Embryo Development: Despite higher stimulation, the number of oocytes retrieved, fertilized embryos, 2PN embryos, and transferable embryos were comparable between HH patients and controls. Fertilization and 2PN rates were also similar.
- Live Birth Rates: The live birth rate (LBR) for the first fresh cycle was higher in controls, but this difference was not statistically significant.
- Cumulative Live Birth Rates (CLBRs): Conservative CLBRs after the first, second, and ≥ third cycles were 43.21%, 58.02%, and 60.49%, respectively. Optimal CLBRs reached 74.19% by the fourth cycle, indicating substantial success with multiple attempts.
- Preterm Birth Rates: Singleton PTB rates were 8.33% (3/36), and twin PTB rates were 30.77% (4/13).
Limitations and Future Work
- Small Sample Size for Twins: The study acknowledges that the small number of twin live births limits definitive conclusions regarding PTB rates in twin pregnancies.
- AMH Not Measured: Due to the study's retrospective nature and long time span, Anti-Müllerian Hormone (AMH) levels, a key marker of ovarian reserve, were not measured. The authors suggest future research should investigate the relationship between AMH and ovarian response in HH patients.
- Need for Further Confirmation: While promising, the findings on PTB rates, particularly for twins, warrant further investigation with larger cohorts.
- Singleton Pregnancy Recommendation: Given the higher PTB risk in twin pregnancies, the authors recommend singleton pregnancies for HH patients.
- Cost-Effectiveness of HMG: The study highlights HMG as a cost-effective option for ovulation induction in HH patients, suggesting its continued use.
Summary updated